Prudential PLC Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Prudential PLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 41.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,280 shares of the biopharmaceutical company's stock after purchasing an additional 1,264 shares during the quarter. Prudential PLC's holdings in Alnylam Pharmaceuticals were worth $1,007,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ALNY. Larson Financial Group LLC boosted its holdings in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares during the period. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $33,000. OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $35,000. Versant Capital Management Inc boosted its holdings in shares of Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the period. Finally, IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Up 5.1 %

Shares of NASDAQ ALNY traded up $11.49 during midday trading on Friday, reaching $237.77. The company had a trading volume of 1,577,336 shares, compared to its average volume of 865,144. The stock has a market cap of $30.93 billion, a PE ratio of -109.57 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm's fifty day moving average price is $253.20 and its 200-day moving average price is $258.26. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Remove Ads

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 in the last quarter. Company insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Sanford C. Bernstein decreased their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Royal Bank of Canada increased their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Finally, Chardan Capital restated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.